Excelsus Structural Solutions SPRL was created in March 2012 as a spin-off company of the Paul Scherrer Institute (PSI), the largest federal research center for natural and engineering sciences within Switzerland. Its main offices are located in Brussels (Belgium) whereas it operates primarily at the PSI synchrotron facility in Switzerland.


In February 2014, Excelsus Structural Solutions (Swiss) AG based in Switzerland was founded to ensure the prompt access of the ESS team to the synchrotron laboratories and facilitate the interaction with the local scientists. Since April 2016, Excelsus Structural Solutions (Swiss) AG is part of Switzerland Innovation PARK INNOVAARE. More on ESS (Swiss) AG transition to Switzerland Innovation PARK INNOVAARE. Interview to founder Dr Fabia Gozzo.


Excelsus Structural Solutions offers easy and affordable access to unique Synchrotron-based characterization tools developed at the Paul Scherrer Institute, to enhance the selection, development and manufacturing of high-quality (bio)pharmaceutical products.


Excelsus Structural Solutions Team of experienced synchrotron scientists with many years of experience in ab-initio structural solution, qualitative and quantitative phase analysis applied to pharmaceuticals will assist you in the definition of the best strategy to takle your specific problem, the conception of the appropriate experimental plan and the development and realization of it. Excelsus' Team will take care of sample preparation, definition of the most appropriate experimental conditions and protocol, data collection, reprocessing, analysis and interpretation and deliver to you a detailed experimental report that suits your specific needs, as defined by you.


Excelsus Structural Solutions team will make available to you the latest advanced Synchrotron X-Ray Powder Diffraction experimental data collection data analysis strategies that have made it possible the detection and quantification of traces of minority phases as low as 0.01% wt in organic pharmaceutical compounds. Level of Detection (LoD) and Level of Quantification (LoQ) as low as 0.01% wt have been recently demonstrated in organic pharmaceutical compounds when using unconventional beamline optics set up developed by Excelsus Team. MORE on 0.01% wt LoD.


The experience of highly qualified professionals in our team providing engineering and scientific services to the industry, while handling proprietary information with high confidentiality standards, is significantly greater than the years that we have been in business.


A network of scientists worldwide allows us to be uniquely positioned to broaden our services with the high standards of Excelsus.



KEYWORDS: Synchrotron X-Ray Powder Diffraction, Pharmaceuticals, Quantitative Phase Analysis, Qualitative Phase Anlaysis, Low Level of Detection, Low Level of Quantification

Excelsus cited in the new "Mediator" section of the EARIV website
31st July 2020
In the context of the CAROTS EU-project, existing Mediators companies have been identified and linked to form a Mediator network. Mediators, such as Excelsus Structural Solutions a ...
Read more ›
Talk by Dr. Fabia Gozzo at the online XRPD meeting from DESY
19th June 2020
Dr. Fabia Gozzo, CEO of Excelsus, has given a talk entitled 'Exploring Synchrotron-XRPD for the characterization of pharmaceuticals' on June, 24th 2020 at 14h10.
Read more ›
Aargauer Zeitung dedicates an article to Fabia Gozzo
19th December 2019
Fabia Gozzo has recently been interviewed by the Aargauer Zeitung and testified how she managed to maintain a good balance between family and work.
Read more ›
Presentation of ESS Case studies at the joint CCG/IG Autumn Meeting
20th November 2019
The joint CCG/IG autumn meeting "By hook or by crook - structural solutions from challenging crystals" was held at GSK site in Stevenage on the 20th November 2019. On thi ...
Read more ›
Our Customers
Privacy    Cookie Policy
realizzazione siti web